Top

Published in:

01-11-2006 | Original Article

The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)

Authors: R. M. Freeman, O. Adekanmi, M. R. Waterfield, A. E. Waterfield, D. Wright, J. Zajicek

Published in: International Urogynecology Journal | Issue 6/2006

Abstract

Objective: To test whether cannabinoids reduce urge incontinence episodes without affecting voiding in patients with multiple sclerosis. This was part of the multicentre trial of the Cannabinoids in Multiple Sclerosis (CAMS) study. Subjects and methods: The CAMS study randomised 630 patients to receive oral administration of cannabis extract, Δ⁹-tetrahydrocannabinol (THC) or matched placebo. For this substudy subjects completed incontinence diaries. Results: All three groups showed a significant reduction, p<0.01, in adjusted episode rate (i.e. correcting for baseline imbalance) from baseline to the end of treatment: cannabis extract, 38%; THC, 33%; and placebo, 18%. Both active treatments showed significant effects over placebo (cannabis extract, p=0.005; THC, p=0.039). Conclusion: The findings are suggestive of a clinical effect of cannabis on incontinence episodes in patients with MS. This is in contrast to the negative finding of the CAMS study, where no difference was seen in the primary outcome of spasticity.

Betts CD, Dmellow MT, Fowler CJ (1993) Urinary symptoms and the neurological features of bladder dysfunction in multiple-sclerosis. J Neurol Neurosurg Psychiatry 56(3):245–250PubMed

Goldstein I, Siroky MB, Sax DS, Krane RJ (1982) Neurourologic abnormalities in multiple-sclerosis. J Urol 128(3):541–545PubMed

Hinson JL, Boone TB (1996) Urodynamics and multiple sclerosis. Urol Clin North Am 23(3):475PubMedCrossRef

Sliwa JA, Bell HK, Mason KD, Gore RM, Nanninga J, Cohen B (1996) Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms. Arch Phys Med Rehabil 77(3):247–251PubMedCrossRef

Nathan PW, Smith NC (1982) The centrifugal pathway for micturition with the spinal cord. J Neurol Neurosurg Psychiatry 21:177CrossRef

Chancellor MB, Blaivas JG (1994) Urological and sexual problems in multiple-sclerosis. Clin Neurosci 2(3–4):189–195PubMed

Gonor SE, Carroll DJ, Metcalfe JB (1985) Vesical dysfunction in multiple-sclerosis. Urology 25(4):429–431PubMedCrossRef

Madersbacher H, Wyndaele JJ, Igawa Y, Chancellor M, Chartier-Kastler E, Kovindha A (2002) Conservative management in neuropathic urinary incontinence. In: Abrams P et al (eds) Incontinence: 2nd international consultation on incontinence, Health Publication Ltd., Plymouth, pp 697–754

De Ridder D, Baert L (2000) Vanilloids and the overactive bladder. BJU Int 86(2):172–180PubMedCrossRef

10.

de Seze M, Wiart L, Ferriere JM, de Seze MP, Joseph PA, Barat M (1999) Intravesical instillation of capsaicin in urology: a review of the literature. Eur Urol 36(4):267–277PubMedCrossRef

11.

Rapp DE, Lucioni A, Katz EE, O’Connor RC, Gerber GS, Bales GT (2004) Use of botulinum-a toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63:1071–1075PubMedCrossRef

12.

Litwiller SE, Frohman EM, Zimmern PE (1999) Multiple sclerosis and the urologist. J Urol 161(3):743–757PubMedCrossRef

13.

Burton TA (1979) Urinary retention following cannabis ingestion. JAMA 242(4):351PubMedCrossRef

14.

Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44–48PubMed

15.

Brady CM, DasGupta R, Wiseman OJ, Dalton CM, Berkley KJ, Fowler CJ (2002) The effect of cannabis based medicinal extract on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. J Neurol Neurosurg Psychiatry 72(1):139

16.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362(9395):1517–1526PubMedCrossRef

17.

Groutz A, Blaivas JG, Chaikin DC, Resnick NM, Engleman K, Anzalone D, Bryzinski B, Wein AJ (2000) Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. J Urol 164(3):698–701PubMedCrossRef

18.

Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104(12):1374–1379PubMed

19.

Lose G, Fantl JA, Victor A, Walter S, Wells TL, Wyman J, Mattiasson A (1998) Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction. Neurourol Urodyn 17(3):255–262PubMedCrossRef

20.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the of the International Standardisation Sub-Committee Continence Society. Neurourol Urodyn 21(2):167–178PubMedCrossRef

21.

Artibani W, Andersen JT, Gajewski JB, Ostergard DR, Raz S, Tubaro A (2002) Imaging and other investigations. in: Abrams P et al (eds) Incontinence: 2nd international consultation on incontinence, Health Publication Ltd., Plymouth, pp 697–754

22.

Goldstein H (1995) Multilevel statistical models, 2nd edn. Arnold, London

23.

Cnaan A, Laird NM, Slasor P (1997) Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16(20):2349–2380PubMedCrossRef

24.

Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14:849–855PubMedCrossRef

25.

Greenland JE, Brading A (1995) The in-vitro effect of delta-9 tetrahydrocannabinol on the detrusor smooth muscle of the pig. Proceedings of the International Continence Society, Sydney, pp 87–88

26.

Ost D, Van der Aa F, De Ridder D (2001) Immunohistochemical study of the cannabinoid receptors CB1 and CB2 in the human bladder. Mult Scler 7(1):S24

27.

Pertwee RG, Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118(8):2053–2058PubMed

28.

Blyweert W, Van der Aa F, De Ridder D (2003) Cannabinoid therapy in detrusor overactivity: local versus systemic effect in a spinalised rat model. Neurourol Urodyn 22(5):379–380

29.

Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155(3):1023–1029PubMedCrossRef

Title: The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)
Authors: R. M. Freeman
O. Adekanmi
M. R. Waterfield
A. E. Waterfield
D. Wright
J. Zajicek
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 6/2006
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-006-0086-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Spontaneous delivery following tension-free vaginal tape procedure

Perineal endometriosis in episiotomy scar with anal sphincter involvement: report of two cases and review of the literature

Urinary retention following tension-free vaginal tape successfully treated by sacral neuromodulation

Urogynecology practice patterns among Air Force obstetricians and gynecologists: survey results

Needle suspension of the bladder neck for stress urinary incontinence: objective results at 11 to 16 years

Postpartum urinary incontinence: a comparison of vaginal delivery, elective, and emergent cesarean section